Hua Medicine is a publicly traded biotechnology company, listed on the Hong Kong Stock Exchange (ticker: 2552) and headquartered in Shanghai, China. Hua is principally focused on curing Type 2 diabetes by restoring the body's natural ability to maintain glucose homeostasis on its own. This autonomous ability to maintain glucose homeostasis is impaired due to the deterioration of the function of the glucose sensing enzyme in the body, glucokinase (GK), located principally in the pancreatic beta-cells and intestines. In-licensed from Roche as pre-clinical compound, Hua has developed dorzagliatin, a GK activator (GKA), into a commercialized medicine approved and reimbursed in China - the only global first-in-class GKA. After the conclusion of one of its Ph3 registration trial, an ~65% diabetes remission rate over a subsequent drug-free 52-week period was observed, the results of which were published in Diabetes, Obesity and Metabolism in 2023.